Госпиталь Ruber Internacional
| Түркия | Австрия | Испания | |
| Нано-пышақ | бастап $9,500 | бастап $25,000 | бастап $12,000 |
| Кибер-пышақ | бастап $4,750 | бастап $50,000 | бастап $30,000 |
| Актиний-225 терапиясы | бастап $22,955 | бастап $55,000 | бастап $45,000 |
| Ұйқыбез ісігін алып тастау | бастап $10,000 | - | - |
Доктор Антонио Кубильо Грасиан Hospital Universitario HM Sanchinarro клиникасында ұйқы безінің нейроэндокриндік ісіктеріне баса назар аудара отырып, онкология саласында мамандандырылған.
Доктор Жауме Капдевила – ас қорыту және ұйқы безі қатерлі ісіктері бойынша жоғары білікті дәрігер, Ллейда университетінің медицина және хирургия мамандығы бойынша дипломы бар және Санта-Креу-и-Сан-Пау ауруханасында медициналық онкология бойынша маманданған. Ол EORTC, ESMO, ENETS, ASCO, GEMCAD, TTD және GETHI сияқты бірнеше кәсіби ұйымдардың мүшесі болып табылады.
Spanish oncology centers stage Pancreatic Neuroendocrine Tumors using AJCC TNM classification and WHO biological grading. Specialized multidisciplinary tumor boards at JCI-accredited clinics evaluate resectability, hormone functionality, and the Ki-67 proliferation index. Key diagnostic tools include 68Ga-DOTATATE PET-CT and high-resolution MRI for precise tumor mapping.
Bookimed Expert Insight: Spain’s top-tier oncology centers often prioritize organ-sparing enucleation for tumors under 2 cm rather than radical resection. Data shows centers like Centro Médico Teknon or Hospital Universitario HM Sanchinarro process thousands of complex oncology cases yearly. This high volume allows their multidisciplinary boards to successfully pivot between surveillance for low-grade tumors and aggressive interventions like PRRT without compromising safety.
Patient Consensus: Patients emphasize the importance of the multidisciplinary tumor board review, noting it provides a clearer roadmap than single-doctor consultations. Many highlight that PET-CT scan results were the ultimate factor in determining if they qualified for specialized nuclear medicine treatments.
Surgery is not always required for pancreatic neuroendocrine tumors. Doctors often recommend active surveillance for small, non-functional tumors under 2 centimeters. Decisions depend on tumor size, growth rate, hormonal activity, and overall health. Advanced metastatic disease sometimes requires systemic therapies instead of primary surgery.
Bookimed Expert Insight: While surgery remains the standard for localized cases, Spain's high-volume centers prioritize multidisciplinary decision-making. At Hospital Ruber Internacional, specialists use 3-Tesla MRI and Da Vinci Xi systems to determine if a patient truly needs an operation. Choosing a facility with both surgical and advanced radiotherapy capabilities ensures you aren't funneled into surgery if non-invasive monitoring is safer.
Patient Consensus: Patients note that for tiny, indolent tumors, regular follow-up scans are often less stressful and safer than major pancreatic surgery. Many emphasize that getting a second opinion from a neuroendocrine specialist is vital before deciding on an invasive procedure.
Systemic therapies for unresectable pancreatic neuroendocrine tumors in Spain focus on controlling tumor growth and managing hormone secretion. Treatment options include somatostatin analogs, targeted therapies like sunitinib, and peptide receptor radionuclide therapy. Spanish oncology centers utilize precise diagnostics to select medication based on tumor grade.
Bookimed Expert Insight: Spanish centers like Hospital Universitario HM Sanchinarro and Grupo GenesisCare offer highly specialized radiation technologies including CyberKnife and Actinium-225 therapy. Data shows that clinics in Madrid and Barcelona often treat over 10,000 patients annually. This high volume allows specialists like Dr. Antonio Cubillo Gracián to refine complex systemic protocols. Patients benefit from facilities that combine JCI-accredited safety standards with access to international research networks.
Patient Consensus: Patients note that understanding the Ki-67 index and receptor status is vital before starting therapy. Many emphasize that finding a center with specific expertise in neuroendocrine tumors significantly changed their treatment sequence.
Spanish oncology centers treat metastatic pancreatic neuroendocrine tumors using multimodal strategies. Options include radical resection for isolated lesions or cytoreductive surgery to remove 70% to 90% of tumor mass. Advanced centers utilize CyberKnife radiosurgery, PRRT, and liver-directed therapies to control disease and manage symptoms.
Bookimed Expert Insight: Spain offers a unique concentration of highly specialized oncology hubs like Hospital Ruber Internacional and HM Sanchinarro in Madrid. These centers serve over 425,000 patients combined each year. This high volume allows surgeons like Dr. Antonio Cubillo Gracián to offer complex procedures such as Irreversible Electroporation (NanoKnife). This technology treats liver tumors near major blood vessels that are often deemed too risky for traditional surgery.
Patient Consensus: Patients note it is important to seek teams that offer a full menu of treatments. They emphasize that treatment shifts based on symptoms like flushing or pain rather than just scan results.
Spain hosts globally recognized centers for Pancreatic Neuroendocrine Tumors (PanNET), led by Hospital Universitari Vall d'Hebron. This facility serves as a European Neuroendocrine Tumor Society (ENETS) Center of Excellence. Other premier institutions include Centro Médico Teknon and Hospital Ruber Internacional for precision oncology.
Bookimed Expert Insight: While many general hospitals treat pancreatic cancer, PanNET patients should prioritize JCI-accredited centers in Madrid or Barcelona. Data shows these cities house facilities like Hospital Ruber Internacional and Centro Médico Teknon. These centers perform thousands of surgeries annually and use advanced CyberKnife technology for neuroendocrine cases.
Patient Consensus: Patients emphasize finding a dedicated neuroendocrine tumor program rather than a general surgery unit. Expert second opinions are highly valued before committing to complex pancreatic resections or nuclear medicine therapies.
International patients can access novel PanNET clinical trials in Spain through major academic oncology centers. Approval depends on meeting strict inclusion criteria like genetic mutations or tumor grades. Spain hosts over 900 annual oncology trials. These often feature advanced therapies like Actinium-225 or NanoKnife technology.
Bookimed Expert Insight: Spanish referral centers like Hospital Universitario HM Sanchinarro handle high patient volumes. Dr. Antonio Cubillo Gracián leads research there while training future oncologists. Our data shows these academic-heavy environments often offer the most reliable pathways into novel protocols. Targeting clinics with dedicated research directors simplifies the transition from standard care to experimental trials.
Patient Consensus: Patients find that having a documented medical dossier ready makes the enrollment process smoother. They note that staying near the clinic is often necessary due to frequent monitoring visits.
Major Spanish private hospitals provide extensive English-language support through dedicated international patient departments. Facilities in Madrid and Barcelona employ fluent oncology specialists. While clinical staff often speak English, administrative support varies. Bookimed manages all logistics, translation, and hospital communication to ensure seamless care.
Bookimed Expert Insight: Data shows that hospital volume directly correlates with language service depth. Large centers like Hospital Universitario HM Sanchinarro and Centro Médico Teknon manage thousands of international cases yearly. These high-volume facilities maintain consistent translation protocols that smaller clinics often lack.
Patient Consensus: Patients note that while surgeons and specialists usually speak fluent English, communication with nursing and administrative staff can be more challenging. They emphasize requesting written English versions of all pathology and scan reports before discharge.